Form 4: BioCryst Pharmaceuticals Director Nancy J. Hutson Increases Stake with Recent Stock Purchase

Director Nancy J. Hutson increased her holdings in BioCryst Pharmaceuticals by purchasing 5,000 shares of common stock at an average price of $6.38 on May 20, 2024.

Summary

• On May 20, 2024, Nancy J. Hutson, a director of BioCryst Pharmaceuticals Inc. (BCRX), purchased 5,000 shares of the company's common stock.
• The shares were acquired at a weighted average price of $6.38, with individual transactions ranging from $6.375 to $6.38.
• Following the transaction, Hutson directly owns 86,818 shares of BioCryst Pharmaceuticals.
• The purchase was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC) on May 22, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's stock purchase, which suggests confidence in the company's future. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into a company's prospects. A director purchasing shares is often viewed positively.

Stakeholder Impact

• The stock purchase could positively influence shareholder sentiment.

Key Dates